About

About Richard Lingard

A career at the intersection

Scientific depth. Commercial execution.

Richard has built and scaled commercial operations for some of the most recognized names in life sciences technology. His defining chapter was at Dotmatics, where he helped grow revenue from £4 million to £16 million in three years. At Adroit AI, he is applying the lessons earned inside category-defining platforms to the needs emerging now.

30+

Years in scientific informatics

4×

Revenue growth in three years at Dotmatics, from £4m to £16m

Major global regions covered by the commercial operation he helped scale

Experience

Scientific Informatics at Scale

Richard has spent over three decades at the forefront of scientific informatics, working across molecular modelling, genomics, cheminformatics, and drug discovery data platforms. His career spans BIOVIA, Thermo Fisher Scientific, Charles River Laboratories, Thomson Reuters, and Dotmatics.

He understands the whole platform journey: why scientists adopt it, how enterprise buyers evaluate it, what makes implementations succeed, and how commercial teams turn specialist software into global infrastructure.

Dotmatics

From £4 Million to £16 Million in Three Years

As SVP of Global Commercial Operations, Richard helped quadruple Dotmatics revenue, doubled the international commercial team, and expanded operations across North America, Europe, Asia, and Japan.

That inside experience matters. Richard knows what made the platform valuable, how its customer relationships were built, and where today’s scientific organisations are beginning to ask for something different.

Explore the Dotmatics chapter ↗

Richard Lingard, scientific informatics executive

The next chapter

Why Richard Founded Adroit AI

After seeing scientific data platforms from every side, Richard kept returning to one issue: chemistry and biology were still separated, valuable data remained difficult to use, and AI readiness was too often promised rather than engineered.

Adroit AI grew from that insight. It brings molecules, targets, reactions, and assays into a unified schema and supports cloud, on-premises, or hybrid deployment. It is not an abstract vision; it is a response shaped by decades of knowing what works.

30+ years

Understanding the platforms scientists rely on—and designing for what they need next.